Results From a Prospective, Open-Label, Phase II Trial of Bendamustine in Refractory or Relapsed T-Cell Lymphomas: The BENTLY Trial

Damaj, Gandhi; Gressin, Rémy; Bouabdallah, Krimo; Cartron, Guillaume; Choufi, Bachra; Gyan, Emmanuel; Banos, Anne; Jaccard, Arnaud; Park, Sophie; Tournilhac, Olivier; Collela, Jean-Marc Schiano-de; Voillat, Laurent; Joly, Bertrand; Gouill, Steven Le; Saad, Alain; Cony‐Makhoul, Pascale; Vilque, Jean-Pierre; Sanhès, Laurence; Tanguy‐Schmidt, Aline; Bubenheim, Michael; Houot, Roch; Diouf, Momar; Marolleau, Jean‐Pierre; Béné, Marie‐Christine; Martin, Antoine; Lamy, Thierry

doi:10.1200/jco.2012.43.7285

Cited by 137 publications

(109 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…66 Responses were seen across multiple histologies, including 41% ORR in PTCL-NOS, but their duration was short (3.5 months), lasting more than 1 year in only 7% of patients. Nevertheless, 2 patients benefitted from this treatment and had the chance to be allotransplanted.…”

Section: Investigational and Off-label Therapiesmentioning

confidence: 98%

Peripheral T-cell lymphoma, not otherwise specified

Broccoli

Zinzani

2017

Blood

View full text Add to dashboard Cite

Peripheral T-cell lymphoma, not otherwise specified, is a broad category of biologically and clinically heterogeneous diseases that cannot be further classified into any other of the existing entities defined by the World Health Organization classification. Anthracycline-containing regimens, namely cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP), nowadays represent the standard first-line treatment; for patients who achieve a satisfactory response, a consolidation by means of autologous stem cell transplantation may offer a greater chance of long-term survival. Several patients, however, display treatment refractoriness or relapse soon after obtaining a response, and just a few of them are suitable transplant candidates. This is why several new agents, with innovative mechanisms of action, have been investigated in this context: pralatrexate, romidepsin, belinostat, and brentuximab vedotin have been approved for relapsed and refractory peripheral T-cell lymphomas based on their activity, although they do not significantly affect survival rates. The incorporation of such new drugs within a CHOP backbone is under investigation to enhance response rates, allow a higher proportion of patients to be transplanted in remission, and prolong survival.

show abstract

Section: Investigational and Off-label Therapiesmentioning

confidence: 98%

Peripheral T-cell lymphoma, not otherwise specified

Broccoli

Zinzani

2017

Blood

View full text Add to dashboard Cite

show abstract

“…31,32,33,34 Consequently, a possible aim of future studies will be the front-line introduction of novel agents in combination with chemotherapy and/or SCT.…”

Section: Discussionmentioning

confidence: 99%

Intensified chemo-immunotherapy with or without stem cell transplantation in newly diagnosed patients with peripheral T-cell lymphoma

et al. 2014

View full text Add to dashboard Cite

The definitive version is available at: La versione definitiva è disponibile alla URL: [http://www.nature.com.offcampus.dam.unito.it/leu/journal/v28/n9/full/leu201479 a.html] Intensified chemo-immunotherapy with or without stem cell transplantation in newly diagnosed patients with peripheral Tcell lymphoma AbstractPeripheral T-cell lymphomas (PTCLs) receiving conventional treatment have a poor clinical outcome. We conducted a phase II study to evaluate the feasibility and efficacy of chemoimmunotherapy in young ( 60 years old, Clin A study) and elderly (>60 and 75 years old, Clin B study) patients with newly diagnosed PTCL. Clin A patients (n=61) received two courses of CHOP (cyclophosphamide, adriamycin, vincristine, prednisone)-21 with alemtuzumab (AL, 30 mg) followed by two courses of high-dose chemotherapy. On the basis of donor availability, patients in response received allogeneic (allo) or autologous (auto) stem cell transplantation (SCT). Clin B patients (n=25) received six courses of CHOP-21 and AL (10 mg). Clin A responding patients were 38 of 61 (62%) and received alloSCT (n=23) or autoSCT (n=14); one complete remission (CR) patient was not transplanted. At a median follow-up of 40 months, the 4-year overall survival (OS), progression-free survival (PFS) and disease-free survival (DFS) rates were 49, 44 and 65%, respectively. In Clin B study, the response rate was 72%. At a median follow-up of 48 months, the 4-year OS, PFS and DFS rates were 31, 26 and 44%, respectively. In conclusion, front-line alloSCT or autoSCT is effective in prolonging DFS in young patients; AL in elderly improved response with no survival benefit.

show abstract

“…Kidney failure was not reported. [21][22][23][24] Bendamustine is effective against indolent lymphomas, 25,26 chronic lymphocytic leukemia, mantle cell lymphoma, 27 large B-cell lymphomas, 28 peripheral T-cell lymphomas, 29,30 HLs [31][32][33] and multiple myelomas. [34][35][36] The doses used are 50-180 mg/m 2 on days 1 and 2 or a total dose of 100-360 mg/m 2 in a single intravenous perfusion over 30-60 min every 21-28 days.…”

Section: Alternatives To Bcnu In Conditioning Regimensmentioning

confidence: 99%

Carmustine replacement in intensive chemotherapy preceding reinjection of autologous HSCs in Hodgkin and non-Hodgkin lymphoma: a review

Damaj

Cornillon

Bouabdallah

et al. 2017

Bone Marrow Transplant

View full text Add to dashboard Cite

High-dose chemotherapy preceding autologous hematopoietic stem cell transplantation (auto-HSCT) is one treatment option for patients with Hodgkin (HL) or non-Hodgkin lymphoma (NHL). The most frequently used intensive chemotherapy is a combination of carmustine (BCNU), etoposide, cytarabine and melphalan (BEAM). However, BCNU is consistently in short supply, and there has been a recent dramatic increase in its cost, necessitating the utilization of conditioning alternatives. The busulfan-based conditioning regimen known as the busulfan-cyclophosphamide-etoposide (BuCyE) combination is the second most-studied conditioning regimen worldwide after BEAM, and it exhibits a benefit/risk ratio that is comparable to that of BEAM. In addition to these two combinations, the present manuscript also summarizes data reported for other conditioning combinations. Owing to the lack of prospective and comparative studies, a comparison of the toxicities and medicoeconomical profiles of these treatments is warranted to identify effective replacements for BCNU-based conditioning.

show abstract

Results From a Prospective, Open-Label, Phase II Trial of Bendamustine in Refractory or Relapsed T-Cell Lymphomas: The BENTLY Trial

Abstract: Bendamustine showed an encouraging high response rate across the two major PTCL subtypes, independent of age and prior treatment, with acceptable toxicity in refractory or relapsed T-cell lymphoma.

Cited by 137 publications

References 17 publications

Peripheral T-cell lymphoma, not otherwise specified

Peripheral T-cell lymphoma, not otherwise specified

Intensified chemo-immunotherapy with or without stem cell transplantation in newly diagnosed patients with peripheral T-cell lymphoma

Carmustine replacement in intensive chemotherapy preceding reinjection of autologous HSCs in Hodgkin and non-Hodgkin lymphoma: a review

Contact Info

Product

Resources

About